



HAL
open science

What is AIDS in the Amazon and the Guianas in the 90-90-90 era?

Mathieu Nacher, Antoine Adenis, Basma Guarmit, Aude Lucarelli, Denis Blanchet, Magalie Pierre Demar, Félix Djossou, Philippe Abboud, Loïc Epelboin, Pierre Couppié

► **To cite this version:**

Mathieu Nacher, Antoine Adenis, Basma Guarmit, Aude Lucarelli, Denis Blanchet, et al.. What is AIDS in the Amazon and the Guianas in the 90-90-90 era?. PLoS ONE, 2020, 15 (7), pp.e0236368. 10.1371/journal.pone.0236368 . inserm-02916297

HAL Id: inserm-02916297

<https://inserm.hal.science/inserm-02916297>

Submitted on 17 Aug 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

What is AIDS in the Amazon and the Guianas in the 90-90-90 era?

Mathieu Nacher^{1,2,3*}, Antoine Adenis^{1,2}, Basma Guarmit², Aude Lucarelli⁴, Denis Blanchet⁵, Magalie Demar^{3,5,6}, Felix Djossou⁷, Philippe Abboud⁷, Loïc Epelboin⁷, Pierre Couppié^{3,8}

1 Centre d'Investigation Clinique Antilles Guyane, INSERM 1424, Centre Hospitalier de Cayenne, Cayenne, French Guiana, **2** COREVIH Guyane, Centre Hospitalier de Cayenne, Cayenne, French Guiana, **3** DFR Santé, Université de Guyane, Cayenne, French Guiana, **4** Hôpital de Jour Adultes, Centre Hospitalier de Cayenne, Cayenne, French Guiana, **5** Laboratory, Centre Hospitalier de Cayenne, Cayenne, French Guiana, **6** UMR TBIP, Université de Guyane, Cayenne, French Guiana, **7** Service des Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne, Cayenne, French Guiana, **8** Service de Dermatologie-vénérologie, Centre Hospitalier de Cayenne, Cayenne, French Guiana

* mathieu.nacher@ch-cayenne.fr



Abstract

OPEN ACCESS

Citation: Nacher M, Adenis A, Guarmit B, Lucarelli A, Blanchet D, Demar M, et al. (2020) What is AIDS in the Amazon and the Guianas in the 90-90-90 era? PLoS ONE 15(7): e0236368. <https://doi.org/10.1371/journal.pone.0236368>

Editor: Ethan Morgan, Ohio State University, UNITED STATES

Received: March 27, 2020

Accepted: July 2, 2020

Published: July 24, 2020

Copyright: © 2020 Nacher et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data may be made available by contacting Pr Mathieu Nacher (mathieu.nacher66@gmail.com). However, under French Law the persons requesting the data should obtain permission with the commission Nationale Informatique et Libertés (CNIL), 3 Place de Fontenoy, 75007 Paris. It is possible to contact Marilyne ABIVEN (director of the indirect right of access service department of the CNIL) at mabiven@cnil.fr. A non-author point of contact is as follows: ciccc@ch-cayenne.fr.

Introduction

In the past decade, new diagnostic methods and strategies have appeared, HIV testing efforts and the generalization of antiretroviral therapy may have influenced the number of opportunistic diagnoses and mortality of HIV-infected patients. To test this hypothesis we compiled data on the top opportunistic infections and causes of early death in the HIV cohort of French Guiana.

Methods

HIV-infected persons followed in Cayenne, Kourou, and Saint Laurent du Maroni hospitals from 2010 to 2019 were studied. Annual incidence of different opportunistic infections and annual deaths are compiled. For patients with opportunistic infections we calculated the proportion of early deaths.

Results

At the time of analysis, among 2 459 patients, (treated and untreated) 90% had a viral load <400 copies, 91% of the patients in the cohort were on antiretroviral treatment, and 94.2% of patients on treatment for over 6 months had undetectable viral loads. Only 9% of patients had CD4 counts under 200 per mm³. Histoplasmosis clearly remained the most frequent (128 cases) opportunistic infection among HIV-infected persons followed by cerebral toxoplasmosis (63 cases) and esophageal candidiasis (41 cases). Cryptococcal meningitis was ranked 5th most frequent opportunistic infection as was tuberculosis (31 cases). The trend for a sharp decline in early deaths continued (3.9% of patients).

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Conclusions

Despite the successes of antiretrovirals, patients presenting with advanced HIV are still common and they are still at risk of dying. Improved diagnosis, and notably systematic screening with appropriate tools are still important areas of potential progress.

Introduction

Nearly a decade ago we showed that the top ranking Human Immunodeficiency Virus (HIV)-related opportunistic infectious diseases in French Guiana, a French territory in South America, were quite different from what is usually described in Europe [1]. Indeed, as immunosuppression grows, the respective frequency of AIDS-defining infections reflects the regional pathogen ecosystem. Hence, disseminated histoplasmosis, an endemic fungal infection often mistaken for tuberculosis, was shown to be the main opportunistic infection and cause of death, usually in patients with advanced HIV and profound immunosuppression, an insight with practical heuristic value in the Guiana Shield ecosystem and the potential to avoid numerous deaths [2]. A good knowledge of the local epidemiology is therefore crucial to guide the clinicians' diagnostic hypotheses, their investigations and urgent therapeutic decisions. In the past decade, knowledge and awareness of regional particularities have evolved and new diagnostic methods and strategies have appeared [3, 4], HIV testing efforts may have reduced the size of the reservoir of undiagnosed HIV infections, and the generalization of antiretroviral therapy has decreased HIV incidence and improved the overall immunity of HIV cohorts [5, 6]. Such evolution is likely to influence the number of diagnoses and mortality of HIV-infected patients [7]. To test this hypothesis we compiled data on the top opportunistic infections and causes of early death (1 month after an opportunistic infection) in the HIV cohort of French Guiana.

Methods

The standards of healthcare in French Guiana are similar to those of metropolitan France [8]. All HIV-positive patients receive free antiretroviral treatments (usually the most recent drugs) regardless of their residence status or income. Medical imagery, viral loads, CD4 counts, genotyping, antiretroviral concentration measurements, a rich diagnostic arsenal are available for routine care. The parasitology-mycology laboratory performs fungal culture, and Pasteur institute performs tuberculosis diagnoses (direct examination, PCR, and culture). The diagnosis of histoplasmosis relies on the identification of histoplasma on direct examination of samples, culture, or histopathology. Antigen testing is not available for routine care in French Guiana.

HIV-infected persons followed in Cayenne, Kourou, and Saint Laurent du Maroni hospitals between January 1, 2010 and December 31, 2019 were enrolled in the French Hospital Database for HIV (FHDH). The database includes most patients followed in French Guiana and nearly all AIDS cases. Trained technicians entered the demographic data, diagnoses, treatments, medical events, viral loads, CD4 and CD8 counts. Annual incidence of different opportunistic infections and annual deaths are compiled. For patients with opportunistic infections we calculated the proportion of early deaths (<1 month after diagnosis).

Patients included in the FHDH give informed consent for the use of their anonymized data and for the publication of anonymized results. This data collection has been approved by the Commission Nationale Informatique et Libertés (CNIL) since 1992 and the cohort has led to several international publications. The data were analyzed with R.

Results

On December 31st 2019, there were 2 459 patients in the active HIV cohort. Between 2012 and 2019 there was an average 5.5% annual increase of the cohort size. The sex ratio is 0.99 except in Western French Guiana where it was female-biased (0.62). The age group distribution was: <15 years (1.5%), 15–39 years (34%), 40–59 years (46%), and 60+ (18.5%). Overall, 33% of patients were born in Haiti (mostly in Cayenne), 18% in Suriname (Mostly in Saint Laurent du Maroni), 14% in France, 10% in Brazil, 8% in Guyana, for 12% the information was not available, and for the remaining 5% in a variety of countries. Among the total cohort, (treated and untreated) 90% had a viral load <400 copies, 91% of the patients in the cohort (1 749/1 921, 108 treatment naive, and 64 interruptions) were on antiretroviral treatment, and 94.2% of patients on treatment for over 6 months had undetectable viral loads (up from 78% in 2012). At the time of analysis, only 9% of patients had CD4 counts under 200 per mm³.

[Fig 1](#) shows the ranking of the most frequent incident AIDS-defining infections in French Guiana between 2012 and 2019. Histoplasmosis clearly remained the most frequent opportunistic infection among HIV-infected persons followed by cerebral toxoplasmosis and esophageal candidiasis. Pneumocystosis which often ranks higher in mainland France was ranked 4th and was followed by cryptococcal meningitis and tuberculosis ([Fig 1](#)).

[Fig 2](#) shows the historical evolution of disseminated histoplasmosis diagnoses and the sharp decline in early deaths (<1 month after diagnosis of histoplasmosis).

[Table 1](#) shows that males, those from Brazil or Suriname, those diagnosed at the advanced HIV stage were more likely to have disseminated histoplasmosis.




Fig 1. Most frequent opportunistic infections in French Guiana: 2012–2019.

<https://doi.org/10.1371/journal.pone.0236368.g001>




Fig 2. Evolution of histoplasmosis diagnoses and deaths < 1 month.

<https://doi.org/10.1371/journal.pone.0236368.g002>

Discussion

The macroscopic emphasis of this work looks at AIDS-defining infections in the HIV cohort during a decade when treatment, diagnosis and care have greatly improved. Although in-depth analyses of each infection would presumably be of interest, this “macro” perspective had its specific merits to help grasp AIDS trends. The present results show that, despite a very high proportion of the cohort on virologically successful antiretroviral treatment, disseminated histoplasmosis remained the most frequent opportunistic infection. The case fatalities within 1-month of diagnosis, a time-frame used to reduce the likelihood of other causes of death [7], has further decreased showing that awareness, aggressive investigations, and presumptive treatment with efficacious antifungal drugs and antiretrovirals [9] leads to good outcomes in most patients with disseminated histoplasmosis. Since our previous analysis of the main opportunistic infections [1], the implementation of systematic screening for cryptococcal antigen using the CrAg LFA may explain why cryptococcosis went from the 8th most frequent to the 5th most frequent opportunistic infection, a feature that surely distinguishes French Guiana from mainland France. On the contrary wasting syndromes were the 4th AIDS defining event before 1996, then the 6th AIDS defining event in 1996–2008 and dropped to the 8th position during the past decade. This suggests that improved diagnoses, and notably systematic screening with appropriate tools allowed progress in the identification of opportunistic agents, notably cryptococcus.

With the arrival of new *Histoplasma* antigen detection methods [10–12], the possibility of screening for histoplasma, analogous to screening for cryptococcus [4], raises a new and important research question: should we screen all patients with less than 200 CD4 for

Table 1. Differences between patients with histoplasmosis and without histoplasmosis.

	No Histoplasmosis N (%)	Histoplasmosis N (%)	P-value*
Sex			
M	1700 (46.8)	126 (68.1)	<0.001
F	1928 (53.2)	59 (31.9)	
Age category (yrs)			
<15	25 (0.7)	1 (0.5)	0.009
15–29	451 (12.4)	11 (5.9)	
30–39	915 (25.2)	52 (28.1)	
40–49	973 (26.8)	61 (33)	
50–59	697 (19.2)	44 (23.8)	
60–69	381 (10.5)	14 (7.6)	
70–79	142 (3.9)	2 (1.1)	
>80	46 (1.3)	0 (0)	
CD4 at diagnosis			
<200	701 (30.9)	88 (72.1)	<0.001
200–350	495 (21.9)	19 (15.6)	
350–500	463 (20.5)	5 (4.1)	
>500	605 (26.7)	10 (8.2)	
Country of birth			
Brazil	318 (10.3)	37 (22.4)	<0.001
Haiti	1029 (33.3)	21 (12.7)	
Suriname	656 (21.2)	67 (40.6)	
French Guiana	144 (4.7)	6 (3.6)	
Guadeloupe	10 (0.3)	0 (0)	
France	463 (15)	13 (7.9)	
Guyana	286 (9.3)	13 (7.9)	
Dominican Republic	63 (2)	2 (1.2)	
Other	117 (3.9)	6 (3.7)	
Contamination mode			
Hétérosexuel	3003 (90.3)	160 (94.1)	0.18
homo/bisexuel	186 (5.6)	2 (1.2)	
TMF	85 (2.6)	4 (2.4)	
Autre	50 (1.5)	4 (2.3)	
City			
Cayenne	2403 (66.2)	93 (50.3)	<0.001
Kourou	935 (25.8)	86 (46.5)	
Saint Laurent	293 (8)	6 (3.2)	

*Chi-square test.

<https://doi.org/10.1371/journal.pone.0236368.t001>

histoplasmosis? Primary prophylaxis is in practice rarely implemented perhaps because of the fear of drug-drug interactions, antifungal resistance selection, and because physicians often expect that antiretroviral therapy will quickly restore immunity. With progress, opportunistic infections seem not so much a priority as before, and diagnosis of opportunistic infections is no longer a specific topic in French HIV expert recommendations. However, despite the successes of antiretrovirals, patients presenting with advanced infections are still not rare and even today they are still at risk of dying [13]. So for French Guiana, access to commercial histoplasma antigen detection test is important if we wish to further reduce severe forms of

disseminated histoplasmosis, and detect the disease in its early stages of dissemination when its clinical presentation is not yet fully patent. For other countries, where awareness and mycological expertise is not present, where liposomal amphotericin is absent, the added value would be even greater [14–16]. This is in total alignment with the Manaus declaration in 2019 recommending access to diagnostic tests and effective treatment for all hospitals in Latin America by 2025, further emphasized by the imminent WHO/PAHO guidelines for the diagnosis and treatment of disseminated histoplasmosis in HIV patients [17].

Author Contributions

Conceptualization: Mathieu Nacher.

Data curation: Mathieu Nacher, Basma Guarmit.

Formal analysis: Mathieu Nacher, Basma Guarmit.

Investigation: Aude Lucarelli, Denis Blanchet, Magalie Demar, Felix Djossou, Philippe Abboud, Loïc Epelboin, Pierre Couppié.

Methodology: Mathieu Nacher.

Validation: Mathieu Nacher, Antoine Adenis, Aude Lucarelli, Denis Blanchet, Magalie Demar, Felix Djossou, Philippe Abboud, Loïc Epelboin, Pierre Couppié.

Writing – original draft: Mathieu Nacher.

Writing – review & editing: Mathieu Nacher, Antoine Adenis.

References

1. Nacher M, Adenis A, Adriouch L, Dufour J, Papot E, Hanf M, et al. What is AIDS in the Amazon and the Guianas? Establishing the burden of disseminated histoplasmosis. *Am J Trop Med Hyg.* 2011; 84: 239–40. <https://doi.org/10.4269/ajtmh.2011.10-0251> PMID: 21292891
2. Vantilcke V, Boukhari R, Jolivet A, Vautrin C, Misslin C, Adenis A, et al. Fever in hospitalized HIV-infected patients in Western French Guiana: first think histoplasmosis. *Int J STD AIDS.* 2014; 25: 656–661. <https://doi.org/10.1177/0956462413516299> PMID: 24598976
3. Hillemann D, Rüscher-Gerdes S, Boehme C, Richter E. Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System. *J Clin Microbiol.* 2011; 49: 1202–1205. <https://doi.org/10.1128/JCM.02268-10> PMID: 21270230
4. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2010; 51: 448–455. <https://doi.org/10.1086/655143> PMID: 20597693
5. Nacher M. L'infection VIH en Guyane: revue historique et tendances actuelles / HIV in French Guiana: historical review and current trends. 2020; 9.
6. Nacher M, Adriouch L, Huber F, Vantilcke V, Djossou F, Elenga N, et al. Modeling of the HIV epidemic and continuum of care in French Guiana. *PLoS One.* 2018; 13: e0197990. <https://doi.org/10.1371/journal.pone.0197990> PMID: 29795698
7. Adenis A, Nacher M, Hanf M, Vantilcke V, Boukhari R, Blanchet D, et al. HIV-associated histoplasmosis early mortality and incidence trends: from neglect to priority. *PLoS Negl Trop Dis.* 2014; 8: e3100. <https://doi.org/10.1371/journal.pntd.0003100> PMID: 25144374
8. Nacher M. Santé Globale et Guyane: Étude descriptive et comparative de quelques grands indicateurs/ Global Health and French Guiana: a descriptive and comparative study of some major indicators. 2020; 10.
9. Nacher M, Adenis A, Blanchet D, Vantilcke V, Demar M, Basurko C, et al. Risk factors for disseminated histoplasmosis in a cohort of HIV-infected patients in French Guiana. *PLoS Negl Trop Dis.* 2014; 8: e2638. <https://doi.org/10.1371/journal.pntd.0002638> PMID: 24498446
10. Nacher M, Blanchet D, Bongomin F, Chakrabarti A, Couppié P, Demar M, et al. *Histoplasma capsulatum* antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low

- and middle income countries: A systematic review of diagnostic accuracy studies. *PLoS Negl Trop Dis*. 2018; 12: e0006802. <https://doi.org/10.1371/journal.pntd.0006802> PMID: 30339674
11. Cáceres DH, Samayoa BE, Medina NG, Tobón AM, Guzmán BJ, Mercado D, et al. Multicenter Validation of Commercial Antigenuria Reagents To Diagnose Progressive Disseminated Histoplasmosis in People Living with HIV/AIDS in Two Latin American Countries. *J Clin Microbiol*. 2018; 56. <https://doi.org/10.1128/JCM.01959-17> PMID: 29563205
 12. Cáceres DH, Scheel CM, Tobon AM, Ahlquist Cleveland A, Restrepo A, Brandt ME, et al. Validation of an enzyme-linked immunosorbent assay that detects *Histoplasma capsulatum* antigenuria in Colombian patients with AIDS for diagnosis and follow-up during therapy. *Clin Vaccine Immunol*. 2014; 21: 1364–8. <https://doi.org/10.1128/CVI.00101-14> PMID: 25008902
 13. Nacher M, Huber F, Adriouch L, Djossou F, Adenis A, Couppié P. Temporal trend of the proportion of patients presenting with advanced HIV in French Guiana: stuck on the asymptote? *BMC Res Notes*. 2018; 11: 831. <https://doi.org/10.1186/s13104-018-3944-y> PMID: 30477588
 14. Adenis AA, Valdes A, Cropet C, McCotter OZ, Derado G, Couppié P, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. *Lancet Infect Dis*. 2018; 18: 1150–1159. [https://doi.org/10.1016/S1473-3099\(18\)30354-2](https://doi.org/10.1016/S1473-3099(18)30354-2) PMID: 30146320
 15. Nacher M, Adenis A, Mc Donald S, Do Socorro Mendonca Gomes M, Singh S, Lopes Lima I, et al. Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage. *PLoS Negl Trop Dis*. 2013; 7: e2319. <https://doi.org/10.1371/journal.pntd.0002319> PMID: 24278485
 16. Cáceres DH, Zuluaga A, Arango-Bustamante K, de Bedout C, Tobon AM, Restrepo A, et al. Implementation of a Training Course Increased the Diagnosis of Histoplasmosis in Colombia. *Am J Trop Med Hyg*. 2015; 93: 662–7. <https://doi.org/10.4269/ajtmh.15-0108> PMID: 26123961
 17. Cáceres DH, Adenis A, de Souza JVB, Gomez BL, Cruz KS, Pasqualotto AC, et al. The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group. *Curr Fungal Infect Rep*. 2019; 13: 244–249.